NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...

n=8), weekly exenatide injections (Bydureon BCise®, n=8), or weekly 1 mg semaglutide injections (Wegovy®, n=8) for a 9-week treatment duration. Changes in weight will be measured. The study is ...

Vivani Medical, Inc. (VANI), on Wednesday, announced promising preclinical data for its semaglutide implant in development ...

Lixisenatide requires daily injections, while newer GLP-1-targeting ... earlier study in Parkinson’s of a similar GLP-1 agonist, exenatide, which was published in The Lancet in 2017.

One major angle has been the race to develop an oral weight loss treatment, which would provide a significant boost to convenience over current treatments that require an injection. As well as ...

ALAMEDA, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical ...

GLP-1 receptor agonists, originally introduced in 2006, have undergone significant advancements over the years. David Ricks, ...

Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...

A total of 30 adults will receive the denosumab regimen of 60 milligrams injection given under the skin every three months for a total of four injections. Meanwhile, a total of 15 adults are needed ...

Iron overload more common among East Asian populations New study raises concerns over serious side effects of weight loss injections Scientists discover brain cells that signal when to stop eating The ...

When giving gluteal injections, it is safest to use the upper outer quadrant. The choice of site for injection must be based on good clinical judgment, using the best evidence available and ...